Medical Annals

In this post, we emphasize the critical need for nontuberculous mycobacteria (NTM) and fungal testing for patients undergoing CAR T-cell therapy. While this innovative treatment has shown effectiveness against certain cancers, it significantly suppresses the immune system, making patients more vulnerable to opportunistic infections...

This post discusses the clinical significance of Torque Teno Virus (TTV) as a biomarker for transplant patients. TTV monitoring helps assess immune function, particularly for solid organ and stem cell transplant recipients, by indicating infection risk and potential organ rejection. Higher TTV loads suggest a greater risk of infection, while lower levels signal a higher chance of rejection. TTV levels can also aid in managing immunosuppression and predicting adverse events in CAR T-cell therapy​.

This post discusses the growing potential of Torque Teno Virus (TTV) testing as a tool for monitoring patient immune status, particularly for those who are immunocompromised, like organ transplant recipients. TTV is prevalent in most adults but is not directly linked to specific diseases. Its significance lies in its use as a marker of immune function, helping clinicians assess infection risks and transplant rejection by monitoring viral loads. This type of testing is especially valuable in guiding treatment decisions for patients with compromised immune systems​.

Cytomegalovirus (CMV) remains a significant concern for transplant recipients due to its potential to cause severe complications, including organ rejection and opportunistic infections. Early detection and regular monitoring are crucial in minimizing these risks. Eurofins Viracor offers advanced diagnostic tools with industry-leading turnaround times, comprehensive testing options, and educational resources to support healthcare providers and patients in managing CMV effectively. Regular CMV screening can help improve patient outcomes by facilitating timely intervention.

Transplant-associated Thrombotic Microangiopathy (TA-TMA) testing offers a comprehensive evaluation of complement pathway regulation. This approach includes assays for Eculizumab, CH50, and sC5b-9, enabling healthcare providers to assess potential deregulation swiftly. With a fast 24-hour turnaround time, the testing allows for quicker, informed treatment decisions, improving patient outcomes by identifying those at risk for organ injury and death from TA-TMA.

Chimeric antigen receptor (CAR) T cell therapy has transformed hematological cancer treatment, with six therapies now approved by the FDA. Four of these therapies (tisa-cel, axi-cel, brexu-cel, and liso-cel) target CD19 using single chain variable fragments (scFvs) derived from the heavy and light chain variable (VH and VL) regions of the monoclonal antibody FMC63.

Eurofins Viracor's hybrid-capture next-generation sequencing (NGS) technology offers a powerful method for detecting fungal and acid-fast bacteria in human specimens. This advanced technique combines target capture with high-throughput sequencing, providing greater sensitivity and specificity than traditional methods. It enables comprehensive detection of multiple pathogens in a single test, helping clinicians diagnose infections, guide treatment, and potentially identify antimicrobial resistance. This method is particularly useful for identifying hard-to-culture organisms and improving patient outcomes through precision diagnostics.

Nontuberculous mycobacteria (NTM) are lung-infecting pathogens, especially affecting those with compromised lung function or weakened immune systems. A 2010 study found about 30 per 100,000 people in the U.S. were infected, and NTM is now more common than tuberculosis. These bacteria are found in the environment and can form biofilms, making treatment challenging. Early diagnosis is key to managing NTM lung disease, as delays can worsen health outcomes. We recently launched a PCR assay to help clinicians detect NTM more effectively, ultimately improving patient care and quality of life...

Our Natural Killer Cell Function Assay provides a detailed assessment of NK cell function, including cytotoxicity and cytokine production, using advanced flow cytometry techniques. By employing standardized protocols and rigorous quality control measures, we ensure accurate and reliable results that facilitate confident clinical decision-making. Monitoring NK cell activity is vital for evaluating immune function, assessing disease progression, and personalizing immunotherapy treatments. We encourage clinicians to optimize this process through proper sample handling, comprehensive antibody panels, and ongoing education in NK cell biology. Together, we aim to improve patient outcomes and satisfaction through informed treatment strategies.

We recognize the significant challenges posed by infectious diseases and the critical need for accurate diagnostics. With over 40 years of experience, we are committed to innovation, continuously advancing our testing capabilities to empower healthcare providers. Our portfolio includes cutting-edge assays such as Next-Generation Sequencing panels, multiplex PCR, and comprehensive serological tests, all designed to deliver rapid and precise diagnostic information. We also emphasize collaboration with academic institutions and industry partners to drive breakthroughs in infectious disease testing. Our dedication to research and development enables us to provide reliable solutions that enhance patient management and public health interventions. Through our innovative testing strategies, we strive to improve patient outcomes and support effective healthcare practices.